21.11.2016 • NewsElaine BurridgeAxensHeurtey

Axens Raises Bid for Heurtey

(c) Thomas Henderson/Getty Images
(c) Thomas Henderson/Getty Images

French engineering and technology provider Axens has raised its bid to acquire rival company Heurtey Petrochem to €25 per share. The Paris-headquartered firm had previously offered €23 per share in cash, in a bid tendered on Oct. 12. Axens said it raised the offer “in order to strengthen the attractiveness of the bid” to Heurtey’s shareholders. The increased price represents a premium of 37.1% over the closing share price of €18.24 on Oct. 10 and a premium of 44.1% over the per share volume-weighted average price over the last three months prior to that date.

Heurtey Petrochem, also based in Paris, is focused on process furnaces for refining, petrochemicals and hydrogen production, and also has a natural-gas treatment business. A wholly owned subsidiary of IFP Energies Nouvelles (IFPEN), Axens is partnering IFP Investissements, also a wholly owned subsidiary of IFPEN, which already owns 36% of Heurtey’s share capital. The board of directors of both IFPEN and Axens have already approved the proposed bid.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read